Vaccine development is ongoing in different countries of the Americas, including Brazil and Cuba. Vaccines that are developed and/or approved for use in these countries may be considered by the national authorities of CARPHA/ CARICOM Member States with the capacity to undertake comprehensive assessments of the quality, efficacy and safety of the vaccines. At this time, the CARPHA CRS does not rely on assessments by Brazil or Cuba for emergency use review procedure for COVID-19 vaccines. The CRS uses regulatory reliance on assessments by national regulatory authorities to make recommendations to Member States. The selection of the national authorities are based on those recognized for the assessment of biologics (biosimilars, vaccines) by the World Health Organization. At this time, the CARPHA CRS will accept these vaccines for review once they have been approved for emergency use listing by the World Health Organization, or approved for emergency use authorization by one of the following regulatory authorities: Medicines and Healthcare Products Regulatory Agency (UK), European Medicines Agency (EMA), Therapeutic Goods Administration (Australia), Health Canada, United States Food and Drug Administration, or Swissmedic.